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Atherosclerosis is an insidious disease with serious morbidity and mortality including 
ischemic heart disease, stroke, and myocardial infarction. This condition is progressive and 
can start early in life eventually leading to large plaques and arterial occlusion. Two key 
components of this process are the immune system and lipids; in particular, LDL which 
accumulates within the arterial walls and macrophages which recognize and engulf 
oxidized-LDL (oxLDL) to form foam cells. Knowing that certain antibodies directed 
against bacterial antigens such as phosphorylcholine (PC) and cardiolipin (CL) show 
 vii 
 viii
opsonizing cross-reactivity with oxLDL it can be proposed that there is a link between 
immune responses to periodontal bacteria and atherosclerosis. The aim of this investigation 
was to determine whether periodontal bacteria are capable of inducing serum antibodies 
potentially involved in cardiovascular diseases; specifically, IgG anti-PC, IgG anti-CL, and 
IgM anti-CL. To test this, 17 subjects with chronic periodontitis received scaling and root 
planing in conjunction with blood sample analysis to determine if periodontal 
instrumentation resulted in changes in these serum antibodies. If plaque bacteria are 
responsible for an immune response then serum levels of these antibodies should decrease 
following periodontal therapy. We found that serum levels of IgG anti-PC, IgG anti-CL, 
and IgM anti-CL decreased following periodontal scaling and root planing but the change 
was significant only for IgG anti-PC (P 0.045). Serum levels of IgM anti-CL approached 
significance (P 0.054). The results support the hypothesis that the immune response to 
periodontal bacterial microflora contributes to serum concentrations of antiphospholipid 
antibodies.   
   
 
 
 
 
 
INTRODUCTION 
 
 
Heart disease is the leading cause of death in North America and results in more 
than 6 million deaths each year.1 Cardiovascular mortality rates account for 29% of all 
deaths despite efforts aimed at controlling conventional risk factors. This condition is 
progressive often starting early in life and eventually leads to large arterial plaques and 
occlusion.2-4 It has been established that smoking, hypertension, hyperlipidemia, diabetes 
mellitus, age and family history are risk factors for atheroma formation5-8 possibly through 
endothelial cell injury.4,9,10 This injury leads to increased endothelial permeability to 
monocytes which migrate into the intima where they engulf lipids and become foam cells. 
Over many years, this initial lesion of foam cells can evolve into an atheroma which could 
potentially rupture and result in thrombus formation. Because the immune system is a key 
component of this process, atherosclerosis is regarded by many as an inflammatory 
disease.11  
 Likewise, periodontitis is an inflammatory condition of the oral cavity which 
affects the dental supporting tissues. It has been suggested that severe generalized 
periodontal disease is found in 8% to 13% of the world’s adult population.12,13 The 
prevalence is lower in children and young adults with an estimated 2% to 5% of North 
Americans between the ages of 11 and 25 being affected.14 Like atherosclerosis, 
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periodontitis is progressive, resulting in destruction of the supporting connective tissue, 
and alveolar bone loss.15,16 This process is the result of the bacteria-host interaction.17 
Endotoxin release by subgingival bacteria causes activation of junctional epithelial and 
vascular endothelial cells which release inflammatory mediators such as Il-8, Il-1α, PGE2, 
and TNFα. Leukocyte and monocyte recruitment to the site is followed by macrophage 
activation and the further release of these cytokines. Continuation of the inflammatory 
state occurs as T-cells, B-cells, and plasma cells become more prominent and antibody 
production begins. The eventual destruction of periodontal connective tissue and bone 
arises in part due to osteoclast activation by factors such as Il-1, TNF-α, and MMP. If 
attachment loss continues the end result of the disease is tooth loss.  
 A vital component of the etiology of periodontitis is the lipopolysaccharide present 
on the outer membrane of Gram-negative periodontal bacteria. This molecule has 3 major 
component parts; the external O-antigen, the core, and the lipid A which is embedded 
within the lipid portion of the outer membrane18 and is responsible for the endotoxin 
properties. Minor lipopolysaccharide antigenic components have also been identified. 
Phosphorylcholine (PC) is one such molecule. It is attached to cell wall polysaccharide and 
lipoteichoic acid19,20 and has been identified in over 30% of the supragingival and 
subgingival flora including Streptococcus oralis, Streptococcus sanguis, Actinomyces 
israelii, Actinomyces naeslundii, Fusobacterium nucleatum, Haemophilus aphrophilus, 
and  Actinobacillus actinomycetemcomitans.21,22 The exact function of PC has been 
difficult to determine but it is possible that certain bacteria may utilize it to gain access to 
endothelial cells23 or to the circulation.24-26 In Gram-positive pneumococcal organisms 
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there are surface proteins that require binding to PC residues of teichoic acid (TA) and 
Lipoteichoic acid (LTA) for proper function.27,28 Cell wall lytic enzymes of these bacteria 
depend on the conversion of TA and LTA associated PC from an inactive to an active 
form.29 Bacterial adherence, colonization, and invasion are also reliant upon surface PC. It 
has been shown that Streptococcus pneumoniae and Actinobacillus 
actinomycetemcomitans invasion of endothelial cells is dependent on the interaction 
between surface PC and endothelial surface receptors for platelet activating factor.23,25  
Since PC is a component of the LPS motif of many bacteria it potentially plays a 
role in prompting a host immune response. Lymphocyte responsiveness studies have 
shown that PC influences polyclonal B-cell differentiation and activation.30,31 Additionally 
there is host production of IgG and IgM antibodies directed against PC which can assist 
monocyte recognition and phagocytosis of the assaulting pathogen. PC positive strains of 
Actinobacillus actinomycetemcomitans and Streptococcus pneumoniae become opsonized 
by anti-PC IgG inducing PMN respiratory bursts.32 Signs of such host-periodontal 
pathogen interplay are not only detected locally but also systemically. In fact, Schenkein21 
demonstrated the ability of periodontal pathogens to produce a systemic response to PC by 
showing that serum levels of antibodies directed toward PC (Anti-PC IgG) were higher in 
patients with attachment loss than in those without. Further, it was found that both PC-
bearing strains of oral bacteria and oxidized low-density lipoproteins (oxLDL) reacted with 
anti-PC IgG from human serum.33 This suggests that antibody produced against certain 
periodontal bacteria will also react with PC-bearing oxLDL34 and therefore magnify the 
uptake of this lipid by foam cells and further the progression of atherosclerosis.   
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Similar to anti-PC is the involvement of the anti-cardiolipin (anti-CL) antibody in 
the upregulation of macrophage phagocytosis of oxLDL in the pathogenesis of 
atherosclerosis. This heightened uptake of oxLDL by macrophages occurs through an 
interaction between the anti-CL antibody and a glycoprotein called β2GPI.  It has been 
demonstrated that serum β2GPI binds specifically to available oxLDL via special ligands 
and that the resulting complex is subsequently targeted by anti-β2GPI antibodies such as 
anti-CL.35,36 The binding of anti-CL to the oxLDL/β2GPI complex keys macrophage 
uptake of the oxLDL and foam cell formation. The atherosclerotic disease process is 
therefore accelerated as these foam cells eventually give rise to arterial plaque formation.  
Cardiolipin is a mitochondrial phospholipid found in mammalian tissues and 
eukaryotic organisms and is also produced by some prokaryotic bacteria. Its location in the 
inner mitochondrial membrane suggests an integral role in normal electron transport and 
energy metabolism.37 Also, periodontal bacteria including Actinobacillus 
actinomycetemcomitans, Porphyromonas gingivalis have been found to possess a peptide 
sequence similar to one on the β2GPI molecule.38,39,40 As such, periodontal infection could 
stimulate antibody production that is cross-reactive with the β2GPI molecule. In addition, 
there is evidence that β2GPI by itself is immunogenic38 possibly compounding these 
responses. 
There are other explanations for the possible association between anti-CL and 
cardiovascular disease. For example, this molecule has also been implicated in arterial and 
venous thrombosis. It has been suggested that a significant proportion of thrombotic 
episodes can be attributed to this and other anti-phospholipid antibodies since 
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approximately 50% of stroke patients under age 5041, and up to 20% of idiopathic DVT 
patients42 are positive for these types of antibodies. β2GPI is a natural anticoagulant43 and 
under normal conditions attaches to vessel wall endothelium preventing thrombus 
formation. When anti-CL are targeted against β2GPI, patients are at an increased risk of 
developing venous/arteriole thrombosis through disruption of coagulation homeostasis. 
Such events are common in patients with a condition known as antiphospholipid syndrome 
which is known for its high incidence of arterial and/or venous thrombosis, recurrent fetal 
loss, and neurologic disorders which commonly develop. It should be noted however that 
although anti-CL antibodies are seen in 2 to 4% of the general population, clinical 
manifestations are not always found.       
  Increasing evidence over the past 10 years suggests a link between periodontal 
disease and atherosclerosis. An analysis of the literature devoted to this topic was done by 
Scannapieco.44 Using strict inclusion criteria, 31 studies were selected for review. Four 
case control studies reported a positive association between indicators of poor oral health 
and atherosclerosis while 1 showed no association. Eleven of 15 cross-sectional studies 
report a modest association between periodontitis and cardiovascular disease while 4 show 
an association with stroke and 1 with peripheral vascular disease. He concluded that 
periodontitis appears to be associated with atherosclerosis induced diseases. 
 The aim of this investigation was to determine whether SRP would lead to a 
reduction in serum antibodies potentially involved in cardiovascular diseases; specifically, 
IgG anti-PC, IgG anti-CL, and IgM anti-CL. If plaque bacteria are responsible for these 
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systemic responses then serum levels of these antibodies should decrease following 
periodontal therapy.
  
METHODS 
 
 
 
Study Population 
Seventeen patients presenting for treatment of generalized chronic periodontitis were 
chosen to participate in this study. The patients were required to be between the ages of 35 
and 60, have a minimum of 5 teeth per quadrant, and a minimum of 7 teeth with ≥5mm of 
attachment loss. Attempts were made to recruit a racially balanced population of both 
males and females. Exclusion criteria included AIDS and other auto-immune disorders, 
immunosuppressant medications, hepatitis or other infectious diseases, pregnancy, 
disabling cardiac or coronary disease, and donation of 450 MLS (one unit) of blood within 
8 weeks prior to the study.  All subjects signed informed consent forms acknowledging 
their willingness to participate in the study. This study was approved by the Institute 
Review Board of Virginia Commonwealth University.   
 Patients received full mouth scaling and root planing performed over 2 separate 
appointments spaced 2 weeks apart. A blood sample was drawn from each patient prior to 
scaling and root planing at the first and second appointment and again at a third visit that 
was 8 weeks following the second appointment. Collected blood samples were processed 
for serum and stored at -20°C. At the first and third visit a clinical examination was 
performed to measure probing depth (PD), attachment loss (AL), bleeding index (BI), 
gingival index (GI), and plaque index (PI).  
 15 
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ELISA for anti-PC IgG 
Measurement of anti-PC concentrations in serum was carried out using a modification of 
the method previously described.45 Immulon 4 HBX ELISA (Dynatech) plates were coated 
with 0.1 ml of PC-BSA diluted to 1.25 µg of PC/ml in 0.005 M phosphate buffer, pH 
7.5, and incubated at room temperature, with shaking, for 15 min. Plates were washed two 
times, with shaking, in a solution containing 0.01 M phosphate buffer, 0.14 M NaCl, and 
0.01% Tween 20 (Fisher) (PBS-Tween). Next, 0.1 ml of sample diluted in PBS-Tween was 
loaded into the coated wells and incubated at room temperature, with shaking, for 30 min. 
Following another two washes with PBS-Tween, 0.1 ml of peroxidase-conjugated, affinity-
purified, rabbit anti-human IgG (Jackson ImmunoResearch) diluted 1/10,000 in PBS-
Tween was added and incubated for 30 min, with shaking, at room temperature. The plates 
were then washed twice in PBS-Tween as above and then washed twice in dH2O (to 
remove residual Tween). Then, 0.1 ml of 3,3',5,5'-tetramethyl-benzidine (100 µg/ml; 
CalBiochem)-0.006% H2O2 in 0.1 M acetate buffer, pH 6.0, was added and incubated at 
room temperature, with shaking, for 30 min, and 25 µl of 2.5 M H2SO4 was then added to 
stop the reaction and initiate the final color change. Plates were read at A450 on a Molecular 
Devices Vmax enzyme-linked immunosorbent assay (ELISA) reader. Serum anti-PC levels 
from the patients were then compared to a standard sample for interpolation.  
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ELISA for anti-CL IgG and IgM    
Measurement of anti-CL concentrations in serum was carried out as directed using kits 
provided by Pharmacia Corporation (Kalamazoo, MI). Microplate wells were washed one 
time with 300µl of Wash Buffer for 20 seconds followed by removal of the Wash Buffer. 
One hundred µl of (cardiolipin IgG or IgM antibody) Calibrators, Controls, and diluted 
(1:101) patient serum were dispensed into appropriate wells and incubated for 30 minutes 
followed by removal from the wells. The plates were then washed 3 times with Wash 
Buffer followed again by liquid removal from the wells. Anti-Human IgG or IgM 
Conjugate (100 µl) was then added to all wells followed by another 30 minute incubation. 
Wells were then emptied of liquid and the washing procedure was repeated 3 more times. 
One hundred µl of Substrate TMB was then placed into all wells and incubated in the dark 
for 10 minutes followed by the addition of 50 µl of Stop Solution into each well. 
Absorbance was read at 450 nm on a Molecular Devices Vmax enzyme-linked 
immunosorbent assay (ELISA) reader. Serum anti-CL levels from the patients were then 
compared to a standard for interpolation. 
 
Data Analysis  
To determine the effect of scaling and root planing on serum levels of IgG anti-PC, IgG 
anti-CL, and IgM anti-CL repeated measures ANOVA was used to analyze the log of mean 
measurements recorded for each visit. Log conversion was performed because the outcome 
data was skewed making it difficult to perform parametric analysis.  Multiple regression 
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analysis was performed to adjust for demographic variables including age, race, sex, 
smoking status, and visit number. A significance level of 0.05 was used.
  
RESULTS 
 
 
 
Demographic Results and Clinical Parameters 
Table 1 provides the patient demographics. Of those that participated in the study, 7 were 
females and 10 were males. There was a total of 4 African American and 13 Caucasian 
participants. Smoking status was broken down into three groups; smoker (Y), never 
smoked (N), and former smoker (F). There were 9 smokers, 4 who had never smoked, and 
4 former smokers. Clinical parameters recorded at visits 1 and 3 are reported in Table 2. 
Differences in PI and GI between visit 1 and 3 reached significance with a P value of 
0.0009 and 0.0064 respectively.  
 
Serum anti-PC IgG measurements 
Serum levels of IgG anti-PC are given in Table 3. At visits 1, 2, and 3 these levels were 
69.39 µg/ml, 61.03 µg/ml, and 63.37 µg/ml respectively with a standard error of ±11.81 
µg/ml. The difference between these values reached significance (P <0.05). Table 4 shows 
the results of multiple regression analysis of the effects of demographic variables on these 
serum levels. Visit number reached significance (P 0.045) while race, sex, age, and 
smoking status did not.  
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Serum anti-CL IgG measurements   
Serum levels of IgG anti-CL are also given in Table 3. These levels were 6.11 U/ml, 6.14 
U/ml, and 5.57 U/ml at visits 1, 2, and 3 respectively with a standard error of ±1.30 U/ml. 
Significance was not reached (P >0.05).   
  
Serum anti-CL IgM measurements 
Serum levels of IgM anti-CL can be found in Table 3. These levels were 5.31 U/ml, 4.87 
U/ml, and 4.00 U/ml at visits 1, 2, and 3 respectively with a standard error of ±1.52 U/ml. 
The difference between these values approached significance with a P value of 0.054. As 
measured by multiple regression analysis (Table 4), demographic variables did not 
significantly influence serum levels of IgM anti-CL (P >0.05). 
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Table 1 
Patient Demographics 
Characteristic Mean SD
Age (years) 45.6  ±7.23
   
Sex n %
M 10 59
F 7 41
Race  0
B 4 24
W 13 76
Smoker  0
F 4 24
N 4 24
Y 9 52
Abbreviations: 
Sex: M = male, F = female 
Race: B = black, W = white 
Smoker: F = former; N = never smoked; Y = smoker 
 
 
 
Table 2 
Clinical Parameters at Visit 1 and Visit 3 
 
Measurement Visit 1 Visit 3 SE P Value 
PD 3.53 3.26 ±0.18 0.1189 
AL 3.04 3.00 ±0.34 0.8557 
PI 1.14 0.71 ±0.13 0.0009 
GI 1.59 1.23 ±0.10 0.0064 
BI 0.59 0.49 ±0.07 0.1458 
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Table 3 
Serum Levels of IgG anti-PC, IgG anti-CL, IgM anti-CL  
 
IgG anti-PC (µg/ml) 
Visit Mean 
1 69.39 
2 61.03 
3 63.37 
Std Error ±11.81  
P Value 0.042 
 
IgG anti-CL (U/ml) 
Visit Mean 
1 6.11 
2 6.14 
3 5.57 
Std Error ±1.30  
P Value 0.174 
 
IgM anti-CL (U/ml) 
Visit Mean 
1 5.31 
2 4.87 
3 4.00 
Std Error ±1.52  
P Value 0.054 
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Table 4 
Multiple Regression Analysis of the Effects of Demographic 
Variables on Serum Levels of IgG anti-PC, IgG anti-CL, IgM anti-CL 
 
IgG anti-PC 
Variable P Value 
Race 0.732 
Sex 0.141 
Smoke 0.240 
Age 0.681 
Visit number 0.045 
 
IgM anti-CL 
Variable P Value 
Race 0.312 
Sex 0.901 
Smoke 0.702 
Age 0.637 
Visit number 0.057 
 
 
 
Discussion 
 
The relationship between poor dental health and atherosclerosis has become a topic 
of interest in health care.46-49 Clinical measures of periodontitis have been found to show a 
positive association with coronary heart disease50-55 and emphasis is now being placed on 
understanding the mechanism of interaction between periodontal disease and 
atherosclerosis. As such, this study has focused on the systemic influence of periodontal 
bacteria by measuring serum levels of anti-PC and anti-CL antibodies before and after 
SRP. A decrease in these values following such treatment would implicate periodontal 
bacteria as a source of these factors and help explain the association between oral infection 
and cardiovascular pathology. It has already been shown that anti-PC directed against 
periodontal pathogens is cross reactive with oxLDL33 which could potentially lead to 
events that culminate in atherosclerotic plaque formation. 
As expected, we found a decrease in serum IgG anti-PC from visit 1 to visit 3. The 
mean serum level prior to initiation of SRP was 69.39 µg/ml. At the 3rd appointment, 2 
months following completion of the periodontal therapy, this was reduced to 63.37 µg/ml. 
The lowest serum level of IgG anti-PC was noted at the second appointment (61.03 µg/ml). 
The slight increase that occurred between visit 2 and 3 may be attributed to the 8 week 
period of time between these two visits which may have allowed recolonization of the 
diseased sites and a subsequent immune response. This could happen if patient plaque 
control was not adequate following completion of scaling and root planing. Loe found that 
with inadequate oral hygiene gingivitis can develop within 10-21 days and that this 
 24 
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gingival inflammation corresponds to increased prevalence in periodontal bacteria.56 Also, 
with inadequate home care and periodontal maintenance, pathogens such as spirochetes 
return to baseline levels by 42 days.57  
Another explanation for the increase in serum antibody between the second and 
third appointments is the possibility that each SRP visit had an “immunization” effect due 
to instrumentation induced bacteremia which resulted in antibody production. In other 
words the periodontal treatment may have had a dual effect by decreasing IgG serum levels 
through reduction of PC bearing bacteria but also slightly increasing these levels due to a 
systemic exposure to the bacteria caused by the hand instrumentation. 
The difference in serum levels of IgG anti-PC between the first and third 
appointment reached significance with a P value of 0.042. The effect of SRP on these 
systemic antibodies was not affected by race, sex, age, or smoking status as demonstrated 
by multiple regression analysis which failed to show any significant correlation between 
these variables and the antibody levels. 
Also measured in this study were serum anti-CL IgG and IgM levels. Because these 
molecules are potential players in vascular plaque and thrombosis formation, their link to 
periodontal bacteria becomes an important issue. Like IgG anti-PC, these two factors 
experienced an overall decrease between visits 1 and 3 which approached significance for 
IgM anti-CL (P value 0.054) but was not significant for IgG anti-CL. The lack of 
significance can be explained in part by the small number of subjects that participated in 
the study. It is likely that increased statistical power with a larger number of patients would 
have resulted in statistically significant reductions in IgM antibody levels. As with anti-PC, 
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multiple regression analysis failed to show any significant correlation between race, sex, 
age, and smoking status and anti-CL levels. 
Our serum measurements of IgG anti-CL were 6.11 U/ml, 6.14 U/ml, and 5.57 
U/ml at visits 1, 2, and 3 respectively. The corresponding IgM anti-CL values were 5.31 
U/ml, 4.87 U/ml, and 4.00 U/ml. The fact that these values are so small may be a reason 
why they change so little following treatment. Amoros58 categorized patients based on IgG 
anti-CL levels: Patients with low (<20 U/ml) antibody titer and patients with medium to 
high (≥20 U/ml) antibody titer. Of 87 patients, 61 were placed in the low titer group and 
only 26 in the medium to high group. It can be assumed that significant antibody induction 
must be present in order to produce a titer ≥20 U/ml. The patients in this study were not 
selected based upon their antibody levels prior the treatment and only about 20% of 
periodontitis patients have anti-CL levels >15 U/ml. Since a number of our patients lacked 
severe periodontitis the induction of anti-CL may have been limited whereas greater 
disease severity may have lead to higher titer levels. It should also be mentioned that auto–
immune diseases such as systemic lupus erythematosus have been linked to the presence of 
serum anti-CL. In our study, by selecting patients that lacked major systemic diseases, we 
eliminated other etiologies of anti-CL antibodies which may explain why our subjects 
expressed these low levels. However, such patient criteria are necessary in order to isolate 
the significance of periodontitis in anti-CL formation.  
It is noted that IgG anti-PC showed a more dramatic response to the periodontal 
treatment than did IgG anti-CL. In fact, IgG anti-CL levels were virtually unchanged 
during the 2 week period between visits 1 and 2. The difference between these two 
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antibody responses can be attributed to the fact that IgG anti-PC is an IgG2 response which 
shows a more rapid decline following antigen removal. Therefore, by the 2nd appointment 
the IgG anti-PC levels should show greater reduction is serum levels than the IgG anti-CL 
levels. 
The fact that SRP resulted in a decrease in anti-CL antibodies provides evidence 
that oral bacteria are a source of these antibodies. Even though it has been found that 
individuals infected with other bacteria and viruses possess these circulating antibodies59 
there has been minimal evidence prior to this study linking periodontal bacteria to these 
molecules. For example, H. pylori, which is known for its colonization of gastric mucosa, 
has been found to increase the risk of coronary heart disease.60 It has also been found that 
there is a 33% prevalence of antibodies reactive with β2GPI in patients with H. pylori 
infections.61 Other bacterial infections that may trigger the production of these antibodies 
range from spirochetes infections such as syphilis and lyme disease to those involving non-
periodontal staphylococcal and streptococcal organisms.62 The current study now provides 
some insight into the role periodontal bacteria may play in this immune response. 
Both PI and GI showed statistically significant reductions from visit 1 to visit 3 
while PD and BI measurements decreased only slightly. Higher values of these clinical 
parameters at visit one would indicate more disease severity which may have lead to higher 
initial serum levels of the measured antibodies and possible greater reductions in these 
titers following SRP. The mean PD at visit 1 and visit 3 was 3.53mm and 3.26mm 
(respectively) while the mean AL measurements was 3.04 mm and 3.00 mm. These 
numbers represent whole mouth means and therefore include many non-diseased sites 
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which would not respond to periodontal therapy. This may explain the minimal change in 
PD and AL that occurred with treatment. The mean PI, GI, and BI at visits 1 and 3 were 
1.14 and 0.71, 1.59 and 1.23, and 0.59 and 0.49. These clinical parameters suggest minimal 
inflammation and plaque. Not only may this explain why there was minimal change in PD 
and AL following SRP but it also suggests that there may have been a more dramatic 
change in serum antibody levels had the patients exhibited greater disease severity with 
corresponding plaque and inflammation.  
A possible flaw in the study design could have been excluding the measurement of 
clinical parameters such as PI, GI, and BI at the second appointment. Because of this it is 
not possible to determine changes in periodontal health or patient home care at the second 
SRP appointment. Instead, we are only able to determine how these indices differ between 
appointments 1 and 3. This makes it difficult to relate the slight increase in serum IgG anti-
PC between visits 2 and 3 to patient plaque control.  
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